Replies to post #436 on Lpath Inc fka LPTN

[mj1234]

I stand corrected, the two I should have posted were:

On July 23, 2015, we announced that the FDA had completed its review of the Investigational New Drug Application (IND) we submitted for Lpathomab and authorized us to initiate the Phase 1 clinical trial to study Lpathomab . We plan to begin this trial upon obtaining investigational review board approvals and anticipate that the first subject will be dosed in September 2015.

AND

We also have a preclinical drug candidate, Altepan, that has now shown positive results in preclinical models of pulmonary fibrosis, asthma, inflammatory bowel disease, and other indications. Altepan is a monoclonal antibody targeting members of the cysteinyl leukotriene family, which are important mediators of inflammatory disorders. Altepan is ready to begin IND-enabling development activities to prepare for an IND submission to the FDA as soon as funding is available.